Amicus Therapeutics (FOLD) stock price, revenue, and financials

Amicus Therapeutics market cap is $3.1 b, and annual revenue was $260.89 m in FY 2020
View Company

$3.1 B

FOLD Mkt cap, 24-Jun-2022

$66.4 M

Amicus Therapeutics Revenue Q1, 2021
Amicus Therapeutics Gross profit (Q1, 2021)59.9 M
Amicus Therapeutics Gross profit margin (Q1, 2021), %90.2%
Amicus Therapeutics Net income (Q1, 2021)-65.7 M
Amicus Therapeutics EBIT (Q1, 2021)-53.1 M
Amicus Therapeutics Cash, 31-Mar-2021184.8 M
Amicus Therapeutics EV3.4 B
Get notified regarding key financial metrics and revenue changes at Amicus TherapeuticsLearn more
Banner background

Amicus Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

21.4m18.4m363.0k1.2m5.0m36.9m91.2m182.2m260.9m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m14.4m22.0m31.0m

Gross profit

4.1m30.7m76.8m160.3m229.8m

Gross profit Margin, %

83%83%84%88%88%

R&D expense

50.9m50.3m41.9m47.6m76.9m104.8m149.3m270.9m286.4m308.4m

General and administrative expense

19.9m19.4m18.9m20.7m47.3m71.2m88.7m127.2m169.9m156.4m

Operating expense total

70.7m69.6m62.8m68.4m124.2m186.0m472.7m405.6m464.3m476.8m

Depreciation and amortization

1.7m1.5m1.8m3.2m3.6m4.2m4.8m8.8m

EBIT

(50.9m)(52.9m)(64.2m)(68.7m)(130.4m)(181.9m)(442.0m)(328.8m)(304.0m)(247.0m)

EBIT margin, %

(237%)(287%)(17681%)(5613%)(3669%)(1197%)(360%)(167%)(95%)

Interest expense

148.0k89.0k

Interest income

160.0k316.0k174.0k223.0k929.0k1.6m4.1m10.5m10.2m3.2m

Pre tax profit

(48.0m)(52.0m)(63.1m)(70.0m)(132.1m)(203.8m)(449.1m)(349.1m)(355.9m)(274.3m)

Income tax expense

(3.6m)(3.2m)(3.5m)(1.1m)(3.7m)(165.1m)(94.0k)478.0k2.6m

Net Income

(44.4m)(48.8m)(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)(356.4m)(276.9m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.0m5.8m7.8m10.6m39.0k456.0k475.0k293.0k2.1m4.2m7.2m10.9m16.7m21.3m20.6m34.0m44.1m48.8m60.5m62.4m67.4m66.4m

Cost of goods sold

344.0k775.0k1.1m1.8m2.6m3.1m4.3m4.1m5.4m5.6m6.6m6.7m8.4m6.5m

Gross profit

1.8m3.4m6.1m9.1m14.1m18.2m16.3m30.0m38.8m43.2m54.0m55.7m59.0m59.9m

Gross profit Margin, %

84%81%85%84%84%85%79%88%88%89%89%89%88%90%

R&D expense

11.6m13.7m14.0m13.7m11.5m12.0m10.7m10.1m10.0m10.0m12.0m16.1m17.2m21.0m23.4m18.3m32.5m30.9m32.0m40.6m40.8m34.7m138.2m64.6m71.0m58.9m89.1m69.6m70.4m64.1m

General and administrative expense

6.7m4.8m4.1m5.8m5.0m4.8m4.8m4.6m5.2m4.8m5.3m6.4m8.3m15.4m15.7m19.3m17.5m19.1m19.3m21.6m27.4m29.2m31.9m44.3m42.6m39.7m40.2m34.7m37.9m46.7m

Operating expense total

18.3m18.6m18.1m19.5m16.5m16.8m15.6m14.7m15.2m14.8m17.3m22.6m25.5m36.4m39.2m37.6m46.7m55.4m53.2m284.3m70.3m65.1m172.5m111.3m115.2m100.5m132.0m107.0m111.8m112.9m

Depreciation and amortization

429.0k412.0k396.0k375.0k508.0k353.0k395.0k673.0k767.0k896.0k823.0k812.0k851.0k969.0k973.0k1.1m991.0k1.2m1.1m1.8m2.0m2.5m1.6m

EBIT

(14.7m)(13.1m)(10.7m)(9.3m)(16.9m)(17.3m)(16.0m)(15.1m)(15.6m)(14.3m)(16.8m)(24.1m)(26.9m)(38.0m)(43.0m)(48.5m)(44.9m)(52.0m)(47.1m)(275.2m)(56.2m)(46.9m)(156.2m)(81.3m)(76.4m)(57.3m)(78.1m)(51.3m)(52.8m)(53.1m)

EBIT margin, %

(364%)(227%)(138%)(88%)(38808%)(3426%)(3003%)(5739%)(2113%)(1248%)(657%)(2531%)(336%)(220%)(758%)(239%)(173%)(118%)(129%)(82%)(78%)(80%)

Interest expense

41.0k32.0k43.0k15.0k19.0k10.0k9.0k

Interest income

46.0k31.0k27.0k116.0k92.0k65.0k46.0k36.0k42.0k36.0k55.0k171.0k158.0k316.0k307.0k331.0k460.0k759.0k753.0k1.2m1.7m2.9m2.7m2.6m2.6m2.8m1.5m865.0k518.0k165.0k

Pre tax profit

(12.6m)(9.8m)(13.1m)(9.3m)(16.3m)(17.5m)(15.3m)(14.6m)(15.9m)(51.5m)(46.9m)(54.9m)(48.1m)(276.3m)(51.3m)(61.5m)(159.2m)(120.1m)(83.8m)(62.1m)(88.6m)(48.8m)(63.3m)(64.1m)

Income tax expense

(453.0k)(253.0k)56.0k49.0k(164.7m)(1.4m)339.0k(51.0k)168.0k717.0k(251.0k)361.0k3.7m727.0k1.6m

Net Income

(12.6m)(9.8m)(13.1m)(9.3m)(16.3m)(17.5m)(15.3m)(14.6m)(15.9m)(14.6m)(17.1m)(24.3m)(27.1m)(37.8m)(43.7m)(51.0m)(46.7m)(55.0m)(48.1m)(111.7m)(49.9m)(61.8m)(159.2m)(120.3m)(84.6m)(61.8m)(88.9m)(52.5m)(64.0m)(65.7m)

Amicus Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

25.7m34.0m43.6m24.1m69.5m187.0m49.1m79.7m142.8m163.2m

Accounts Receivable

5.0m3.2m759.0k1.3m9.5m22.0m33.3m46.9m

Prepaid Expenses

5.9m2.3m5.5m2.9m2.6m19.3m16.6m20.0m29.7m

Inventories

3.4m4.6m8.4m14.0m19.6m

Current Assets

66.6m104.6m88.3m154.6m216.6m340.1m392.0m551.1m520.1m579.5m

PP&E

2.4m5.0m4.1m2.8m6.2m9.1m11.4m47.7m43.9m

Goodwill

11.6m11.6m197.8m197.8m197.8m197.8m197.8m

Total Assets

69.8m110.1m127.6m210.0m908.4m1.0b627.0m790.0m850.2m886.5m

Accounts Payable

9.7m2.1m2.1m5.9m16.5m185.5m7.9m6.6m21.7m17.1m

Short-term debt

299.0k6.9m

Current Liabilities

19.3m9.2m10.5m20.2m73.6m111.0m70.0m86.1m128.8m129.7m

Long-term debt

41.6m53.5m434.9m

Total Debt

53.5m441.7m

Total Liabilities

447.0m373.8m600.1m

Common Stock

407.0k556.0k679.0k1.0m1.3m1.7m1.9m2.6m2.7m

Additional Paid-in Capital

299.3m387.5m423.6m568.7m917.5m1.1b1.4b1.7b2.2b2.3b

Retained Earnings

(270.1m)(318.9m)(378.5m)(447.4m)(579.6m)(779.6m)(1.1b)(1.4b)(1.8b)(2.0b)

Total Equity

29.6m69.2m45.8m122.2m347.8m360.2m352.9m342.9m476.4m286.4m

Financial Leverage

2.4 x1.6 x2.8 x1.7 x2.6 x2.9 x1.8 x2.3 x1.8 x3.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

25.8m22.8m24.5m28.9m24.3m26.7m23.5m30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m96.3m220.6m166.3m123.2m164.6m210.6m184.8m

Accounts Receivable

2.0m3.8m4.3m7.2m3.2m1.3m1.0m2.1m38.0k475.0k293.0k864.0k1.9m3.8m6.0m10.8m15.1m14.2m23.0m28.7m33.7m40.6m43.0m44.8m44.9m

Prepaid Expenses

3.1m3.0m2.8m2.7m3.1m1.8m2.0m1.7m1.8m951.0k1.8m2.5m3.6m3.5m2.7m3.3m5.2m10.8m6.0m6.2m10.6m14.4m16.2m13.6m20.1m19.6m15.7m18.3m15.6m21.7m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m8.2m10.4m9.2m12.8m13.0m15.8m18.8m

Current Assets

88.1m76.4m115.3m105.7m112.5m87.8m77.2m64.3m73.5m79.4m87.2m151.3m365.0m240.1m168.5m217.7m221.7m296.2m241.0m431.0m592.0m576.2m601.0m483.0m634.9m576.7m407.9m383.9m585.3m502.9m

PP&E

1.9m1.8m5.1m5.5m5.3m5.0m4.7m4.4m3.7m3.4m3.1m3.1m3.4m3.9m8.4m10.2m10.2m9.7m10.5m9.6m8.9m9.1m10.7m13.3m15.3m34.7m47.7m46.9m44.6m43.4m

Goodwill

11.6m11.6m11.6m11.6m11.6m207.6m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m197.8m

Total Assets

90.3m78.9m120.8m111.6m118.2m93.2m82.3m69.1m112.4m118.0m125.5m192.6m403.9m986.7m862.9m914.0m918.2m993.4m939.0m680.8m870.0m825.9m838.6m764.7m918.0m882.3m738.3m701.5m900.5m810.0m

Accounts Payable

7.0m8.1m8.4m9.1m9.4m6.4m9.0m8.2m9.2m9.9m11.3m15.8m16.9m30.6m22.5m23.8m29.0m39.6m35.6m53.7m43.7m41.6m54.3m60.6m84.1m81.5m16.2m14.3m14.8m16.1m

Short-term debt

7.5m8.5m7.4m6.8m

Current Liabilities

16.9m18.6m17.8m17.8m9.9m8.0m10.0m8.6m9.4m11.2m13.8m21.0m16.9m35.9m64.4m80.5m85.6m109.6m100.7m68.2m140.7m53.0m65.9m65.9m89.5m93.1m91.7m108.3m111.7m99.7m

Long-term debt

38.5m21.9m22.0m36.3m49.7m54.7m45.9m433.2m434.2m

Total Debt

38.5m21.9m22.0m36.3m49.7m62.2m54.4m440.6m441.0m

Total Liabilities

348.4m264.0m427.6m313.0m318.0m334.0m335.8m340.5m580.3m559.1m

Common Stock

406.0k407.0k524.0k524.0k554.0k556.0k556.0k556.0k703.0k789.0k853.0k1.0m1.2m1.3m1.3m1.4m1.5m1.5m1.5m1.7m1.9m1.9m1.9m2.3m2.6m2.6m2.6m2.6m2.6m2.7m

Additional Paid-in Capital

295.9m297.8m363.5m365.2m385.0m389.1m390.7m392.2m424.8m444.6m468.7m574.8m826.6m914.3m921.2m990.0m1.0b1.1b1.1b1.4b1.6b1.7b1.7b2.0b2.2b2.2b2.2b2.3b2.3b2.4b

Retained Earnings

(251.7m)(261.4m)(283.2m)(292.6m)(308.9m)(336.3m)(351.7m)(366.3m)(394.5m)(409.1m)(426.2m)(471.7m)(498.9m)(536.7m)(623.3m)(674.3m)(721.0m)(834.6m)(882.7m)(994.4m)(1.1b)(1.2b)(1.3b)(1.5b)(1.6b)(1.7b)(1.9b)(1.9b)(2.0b)(2.1b)

Total Equity

44.6m36.8m80.8m73.2m76.8m53.3m39.6m26.5m31.1m36.3m43.3m104.0m328.9m378.8m311.6m334.2m336.6m310.8m266.9m409.7m521.6m561.9m411.0m451.7m600.1m548.3m402.6m361.0m320.3m250.9m

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

2 x2.1 x1.5 x1.5 x1.5 x1.7 x2.1 x2.6 x3.6 x3.2 x2.9 x1.9 x1.2 x2.6 x2.8 x2.7 x2.7 x3.2 x3.5 x1.7 x1.7 x1.5 x2 x1.7 x1.5 x1.6 x1.8 x1.9 x2.8 x3.2 x

Amicus Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(44.4m)(48.8m)(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)(356.4m)(276.9m)

Depreciation and Amortization

1.6m1.7m1.7m1.5m1.8m3.2m3.6m4.2m4.8m8.8m

Accounts Receivable

(1.4m)(7.7m)(13.3m)(11.1m)(11.2m)

Inventories

(3.7m)(897.0k)(4.2m)(5.1m)(4.6m)

Accounts Payable

1.4m(863.0k)(613.0k)6.2m15.5m7.1m12.6m17.1m46.7m(10.6m)

Cash From Operating Activities

(49.4m)(33.7m)(45.8m)(51.7m)(100.1m)(150.5m)(215.5m)(300.0m)(250.4m)(233.3m)

Purchases of PP&E

(1.4m)(4.3m)(695.0k)(238.0k)(4.8m)(6.0m)(4.5m)(6.3m)(20.0m)(3.2m)

Cash From Investing Activities

46.5m(39.4m)26.1m(107.1m)(145.3m)(4.5m)(171.2m)(121.2m)95.2m(13.6m)

Long-term Borrowings

(40.0k)(193.0k)(308.0k)(334.0k)(420.0k)(155.3m)

Cash From Financing Activities

(934.0k)81.5m29.4m139.2m290.9m272.7m247.4m450.8m217.5m262.9m

Net Change in Cash

(3.9m)8.3m9.7m(19.6m)45.4m117.5m(138.0m)31.1m64.0m19.8m

Interest Paid

149.0k84.0k30.0k1.2m605.0k3.0m7.4m7.5m17.0m24.7m

Income Taxes Paid

10.4m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(26.0m)(35.7m)(13.1m)(22.5m)(38.8m)(17.5m)(32.8m)(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)(120.3m)(204.8m)(266.7m)(88.9m)(141.4m)(205.5m)(65.7m)

Depreciation and Amortization

864.0k1.2m420.0k862.0k1.3m439.0k889.0k1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m991.0k2.1m3.3m1.8m3.8m6.3m1.6m

Accounts Receivable

(863.0k)(512.0k)(2.2m)(4.3m)(1.0m)(6.0m)(5.2m)(1.0m)(6.8m)(12.6m)(8.4m)(10.4m)(10.8m)839.0k

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)345.0k(1.9m)(2.0m)(251.0k)1.4m2.2m741.0k

Accounts Payable

(1.3m)(192.0k)(1.3m)(641.0k)(280.0k)(2.4m)173.0k(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)(4.3m)13.0m(10.3m)(11.8m)3.7m(8.9m)12.5m8.7m(35.3m)(23.9m)(23.4m)(40.2m)

Cash From Operating Activities

(23.9m)(36.9m)(8.0m)(19.2m)(26.4m)(13.9m)(24.2m)(37.7m)(10.2m)(22.0m)(37.2m)(21.0m)(43.6m)(64.6m)(44.9m)(77.7m)(118.5m)(49.8m)(91.8m)(141.7m)(49.5m)(106.5m)(239.3m)(78.5m)(137.0m)(192.6m)(107.9m)(141.5m)(183.5m)(72.4m)

Purchases of PP&E

(182.0k)(398.0k)(3.1m)(3.9m)(4.2m)(372.0k)(575.0k)(645.0k)(40.0k)(132.0k)(192.0k)(753.0k)(1.4m)(2.2m)(2.9m)(4.6m)(5.5m)(732.0k)(2.3m)(3.4m)(1.9m)(4.6m)(2.9m)(5.1m)(9.1m)(806.0k)(1.9m)(2.2m)(868.0k)

Capital Expenditures

(819.0k)

Cash From Investing Activities

20.4m30.8m(56.7m)(40.8m)(56.0m)6.8m13.9m34.0m(5.8m)2.1m(27.3m)21.7m31.3m(230.7m)(442.0k)(10.2m)(39.9m)(92.4m)(48.9m)(222.8m)(182.6m)(171.9m)(57.4m)80.1m65.0m68.2m93.2m163.3m9.2m86.6m

Long-term Borrowings

(40.0k)(40.0k)(47.0k)(118.0k)(71.0k)(142.0k)(212.0k)(71.0k)(142.0k)(218.0k)(75.0k)(98.0k)(177.0k)(21.0k)(38.0k)(155.3m)(368.0k)

Cash From Financing Activities

(318.0k)(621.0k)63.6m63.2m81.0m(100.0k)(199.0k)(299.0k)(85.0k)18.2m40.5m4.1m237.2m290.7m(502.0k)82.8m122.4m(95.0k)(9.6m)240.6m296.6m303.6m450.4m17.4m213.8m214.3m(1.5m)2.6m241.3m8.8m

Net Change in Cash

(3.8m)(6.8m)(1.1m)3.2m(1.4m)(7.2m)(10.5m)(3.9m)(16.1m)(1.7m)(24.0m)4.8m224.9m(4.6m)(46.0m)(5.8m)(36.4m)(142.3m)(149.6m)(122.9m)65.3m24.2m152.6m16.6m140.8m87.3m(20.4m)20.9m67.1m21.9m

Interest Paid

89.0k121.0k20.0k50.0k72.0k7.0k16.0k24.0k208.0k537.0k864.0k209.0k605.0k605.0k276.0k284.0k12.0k3.7m3.7m12.0k3.8m3.8m4.8m9.3m13.1m3.7m10.7m16.7m7.5m

Income Taxes Paid

2.5m

Free Cash Flow

(50.3m)

Amicus Therapeutics Ratios

USDQ2, 2011

Financial Leverage

2 x

Amicus Therapeutics Employee Rating

2.966 votes
Culture & Values
3.1
Work/Life Balance
3.1
Senior Management
2.8
Salary & Benefits
3.4
Career Opportunities
3.1
Source
View Amicus Therapeutics profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more